Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: A dose-escalation, open-label, pharmacokinetic, phase 1 study

The Lancet Haematology

Volumn 3, Issue 4, 2016, Pages e196-e204

  Amorim, Sandy ^a   Stathis, Anastasios ^b   Gleeson, Mary ^c   Iyengar, Sunil ^c   Magarotto, Valeria ^d   Leleu, Xavier ^e   Morschhauser, Franck ^e   Karlin, Lionel ^f   Broussais, Florence ^g   Rezai, Keyvan ^h   Herait, Patrice ⁱ   Kahatt, Carmen ^j   Lokiec, François ^h   Salles, Gilles ^f   Facon, Thierry ^e   Palumbo, Antonio ^d   Cunningham, David ^c   Zucca, Emanuele ^b   Thieblemont, Catherine ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^c ROYAL MARSDEN HOSPITAL   (United Kingdom)

^d UNIVERSITY OF TURIN   (Italy)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g INSTITUT PAOLI CALMETTES   (France)

^h INSTITUT CURIE   (France)

ⁱ Oncoethix SA (now Oncoethix GmbH)   (Switzerland)

^j Oncology Therapeutic Development   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) N (4 HYDROXYPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETAMIDE; MYC PROTEIN; PROTEIN BCL 2; ACETANILIDE DERIVATIVE; ANTINEOPLASTIC AGENT; BIRABRESIB; FUSED HETEROCYCLIC RINGS;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; BLOOD SAMPLING; CANCER FATIGUE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DYSGEUSIA; EPISTAXIS; FEMALE; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; HYPONATREMIA; IMMUNOHISTOCHEMISTRY; LYMPHOMA; MALE; MIDDLE AGED; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECTUM HEMORRHAGE; TANDEM MASS SPECTROMETRY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VOMITING; CLINICAL TRIAL; DRUG ADMINISTRATION; FRANCE; ITALY; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; SWITZERLAND; UNITED KINGDOM;

ACETANILIDES; AGED; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; ITALY; LYMPHOMA; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTIPLE MYELOMA; SWITZERLAND; UNITED KINGDOM;

EID: 84962488380     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(16)00021-1     Document Type: Article

References (26)

1. Filippakopoulos P, Knapp S Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov 2014, 13:337-356.
2. Lovén J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013, 153:320-334.
3. Chapuy B, McKeown MR, Lin CY, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 2013, 24:777-790.
4. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
5. Noel JK, Iwata K, Ooike S, Sugahara K, Nakamura H, Daibata M Development of the BET bromodomain inhibitor OTX015. Mol Cancer Ther 2013, 12:C244. (abstr).
6. Boi M, Gaudio E, Bonetti P, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res 2015, 21:1628-1638.
7. Trabucco SE, Gerstein RM, Evens AM, et al. Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma. Clin Cancer Res 2015, 21:113-122.
8. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
9. Chesi M, Matthews GM, Garbitt VM, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012, 120:376-385.
10. Berthon C, Raffoux E, Thomas X, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. Lancet Haematol 2016, published online March 18. http://dx.doi.org/10.1016/S2352-3026(15)00247-1.
11. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
12. Odore E, Lokiec F, Weill S, et al. Development and validation of an UPLC-MS/MS method for quantitative analysis of OTX015 in human plasma samples. Anal Methods 2014, 6:9108-9115.
13. Odore E, Lokiec F, Cvitkovic E, et al. Phase I population pharmacokinetic assessment of the oral bromodomain inhibitor OTX015 in patients with haematologic malignancies. Clin Pharmacokinet 2015, published online Sept 4. 10.1007/s40262-015-0327-6.
14. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
15. Durie BGM, Harousseau J-L, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
16. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103:275-282.
17. Pfreundschuh M Growing importance of MYC/BCL2 immunohistochemistry in diffuse large B-cell lymphomas. J Clin Oncol 2012, 30:3433-3435.
18. Mottamal M, Zheng S, Huang TL, Wang G Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules 2015, 20:3898-3941.
19. Coudé M-M, Braun T, Berrou J, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget 2015, 6:17698-17712.
20. Whitfield JR, Soucek L Tumor microenvironment: becoming sick of Myc. Cell Mol Life Sci 2012, 69:931-934.
21. Dang CV MYC on the path to cancer. Cell 2012, 149:22-35.
22. Petrich AM, Nabhan C, Smith SM MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches. Cancer 2014, 120:3884-3895.
23. Perry AM, Alvarado-Bernal Y, Laurini JA, et al. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab. Br J Haematol 2014, 165:382-391.
24. Thieblemont C, Brière J MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?. Blood 2013, 121:2165-2166.
25. Bhadury J, Nilsson L, Green L, Zhoulei L, Gesner E, Muralidharan S BET bromodomain inhibitors abrogate cell cycle progression and induces apoptosis in Myc-induced mouse lymphoma cells without affecting MYC transcription. Abstract 5495. Cancer Res 2014, 74:5495.
26. Bhadury J, Nilsson LM, Muralidharan SV, et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc Natl Acad Sci USA 2014, 111:E2721-E2730.